Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants

In July 2014, the Committee on Infectious Diseases (COID) updated their guidance on the use of palivizumab, recommending against use in preterm infants 29 to 35 weeks' gestational age (wGA). A primary data source cited to support this significant change was the low respiratory syncytial virus (...

Descripción completa

Detalles Bibliográficos
Autores principales: DeVincenzo, John P., Ambrose, Christopher S., Makari, Doris, Weiner, Leonard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962937/
https://www.ncbi.nlm.nih.gov/pubmed/26889568
http://dx.doi.org/10.1080/21645515.2015.1115936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962937/
https://www.ncbi.nlm.nih.gov/pubmed/26889568
http://dx.doi.org/10.1080/21645515.2015.1115936

Ejemplares similares